Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-hour intraocular pressure profile study of tafluprost 0.0015% in glaucoma or ocular hypertension
ChiCTR-ONC-14004780Phase 4Recruiting
- Sponsor
- Santen Pharmaceutical
- Start
- Jun 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tafluprost in open-angle glaucoma (OAG), primary angle-closure glaucoma (PACG) and ocular hypertension, sponsored by Santen Pharmaceutical. Primary endpoint: 24-hour intraocular pressure variation. Started Jun 2014; status: recruiting.
02
Drugs
tafluprost
03
Conditions
open-angle glaucoma (OAG)primary angle-closure glaucoma (PACG)ocular hypertension
Beyond the preview
Go deeper on ChiCTR-ONC-14004780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONC-14004780.